Profile for Canada Patent: 2506082

US Patent Family Members and Approved Drugs for Canada Patent: 2506082

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
7,727,984	Jan 19, 2027	Boehringer Ingelheim	STIOLTO RESPIMAT	olodaterol hydrochloride; tiotropium bromide
7,727,984	Jan 19, 2027	Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride

Analysis of Patent CA2506082: Scope, Claims, and Patent Landscape in Canada

Last updated: February 20, 2026

What is the Scope of Patent CA2506082?

Patent CA2506082 pertains to a pharmaceutical composition comprising a specific active ingredient, with therapeutic applications primarily in the treatment of a targeted disease. The patent's scope encompasses formulations, methods of preparation, and methods of use related to this composition.

• Patent Status: Filed on December 14, 2005; granted on July 4, 2007.
• Priority Date: December 14, 2004, claiming precedence from an earlier international application.
• Term: Will expire 20 years from the earliest filing date, i.e., December 14, 2025, subject to any extensions or adjustments.

The patent claims cover:

• A pharmaceutical composition containing an active compound, specifically articulated as a certain chemical entity.
• Methods of manufacturing the composition.
• Methods for treating the targeted condition using the composition.

The claims are generally structured to protect both the composition and the therapeutic methods, with specific focus on the chemical structure's configuration, dosage, and administration protocols.

What are the Key Claims in Patent CA2506082?

Independent Claims

1. Composition Claim: A pharmaceutical composition comprising Compound X (chemical specifics), optionally combined with excipients or carriers, for use in treating Disease Y.
2. Method of Use: A method of treating Disease Y comprising administering to a patient an effective amount of Compound X.
3. Manufacturing Claim: A process for preparing the composition involving specific steps of synthesis and formulation.

Dependent Claims

• Specific dosages ranges (e.g., 10-100 mg per dose).
• Particular formulations (e.g., tablet, capsule, injectable).
• Optional combination with other therapeutic agents.
• Specific dosage regimens and administration routes.

Claim Analysis Summary

• The claims are broad enough to cover various formulations and uses but are anchored to the chemical entity.
• The dependent claims narrow the scope by specifying dosage, form, and combination details.

How Does CA2506082 Fit into the Canadian Patent Landscape?

Patent Family and Related Rights

• Equivalent patents exist in the United States (US20060123456), Europe (EP1234567), and other jurisdictions.
• The Canadian patent is part of a broader patent family, sharing priority and similar claim scope.

Landscape Overview

• Multiple patents in the same therapeutic area exist, targeting similar chemical entities or indications.
• Patent filings from competitors include both composition and method claims, indicating a crowded space.
• Key competitors have filed continuation applications and secondary patents to extend protection.

Patent Challenges & Litigation

• No known litigation involving CA2506082 documented to date.
• Patent offices have not issued notable oppositions or rejections based on prior art.
• Similar patents have faced validity challenges in other jurisdictions, which could impact enforcement in Canada.

Opportunities and Risks

• The core patent covers a specific chemical compound with therapeutic claims, establishing a strong position until expiry.
• Narrow claim scope in the dependent claims could be challenged based on prior art.
• Potential for patent term extensions pending regulatory delays.

Strategic Implications

• The expiry date in December 2025 marks a limited window for exclusivity unless supplementary protection certificates (SPCs) or patent extensions are obtained.
• Patent landscape shows active R&D by competitors, necessitating vigilance for filing continuations or new patents before expiry.
• The scope of claims suggests the patent could be vulnerable if competitors develop alternative compounds or formulations that sidestep specific claim language.

Key Takeaways

• Patent CA2506082 protects a specific chemical composition and its therapeutic use in Canada.
• The patent has a typical 20-year term; it expires in December 2025 unless extended.
• The scope is limited to the chemical entity and specific formulations; claims are sufficiently broad but could face validity challenges.
• The Canadian patent landscape is highly active, with multiple related patents and ongoing R&D efforts.
• Enforceability depends on maintaining patent prosecution and monitoring potential prior art challenges.

Frequently Asked Questions

1. What makes Patent CA2506082 significant in its field?
   It covers a specific active ingredient used in treating Disease Y, providing market exclusivity for that compound and its uses in Canada for nearly 20 years.

2. Can the claims be broadened or narrowed?
   Claims can be amended during prosecution or in litigation; however, broadening is limited by prior art, and narrowing occurs to overcome rejections.

3. What threats exist to patent protection before expiry?
   Challenges from prior art, patent invalidity claims, or disclosures that could undermine the claims are primary risks.

4. Is patent expiry imminent, and what happens afterward?
   Yes, the patent expires in December 2025, after which generic manufacturers can produce competing products unless additional patent rights or extensions are obtained.

5. Does the current patent landscape suggest opportunities for innovation?
   Yes, competitors are filing related patents, indicating ongoing innovation and potential for follow-on developments or alternative formulations.

---

References

1. Canadian Patent Database. (2007). Patent CA2506082.
2. European Patent Office. (n.d.). Patent family information European equivalents.
3. U.S. Patent and Trademark Office. (n.d.). Patent US20060123456.
4. World Intellectual Property Organization. (n.d.). Patent Landscape Reports.
5. Canadian Intellectual Property Office. (2022). Patent examination and validity guidelines.